Bristol-Myers Squibb Stock - Analyst consensus and valuation snapshot
17.06.2026 - 16:20:32 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/17/2026, 16:17 CET. Details in the imprint.
Bristol-Myers Squibb (US1101221083) remains under close watch from Wall Street analysts as consensus targets still imply upside from the current share price. Analyst data show a moderate expected gain and highlight a valuation discount versus the broader pharmaceutical group.
All news and data on Bristol-Myers Squibb stock
Key figures, company announcements and historic reports on Bristol-Myers Squibb stock can be found bundled on our topic page and in the company’s investor relations section.
What consensus data show
According to analyst data compiled by Financhill, the average 12-month price target for Bristol-Myers Squibb stands at $63.08, compared with a recent price of about $56.24, implying an upside potential of roughly 12%. Financhill’s consensus overview also reflects a mix of Buy, Hold and Sell recommendations.
The same data set notes that the stock’s current valuation multiples, such as the forward price-to-earnings ratio, remain below those of many large-cap pharmaceutical peers. This discount is often linked by analysts to patent expiries, competitive pressures and the need to ramp up newer product launches.
How analysts frame the story
Several analyst commentaries cited by Financhill emphasize that Bristol-Myers Squibb’s pipeline and recent launches could gradually offset revenue headwinds from older blockbuster drugs facing loss of exclusivity. The consensus breakdown indicates that positive ratings often hinge on execution in oncology and cardiovascular franchises.
At the same time, more cautious analysts flag uncertainties around reimbursement, competition in immuno-oncology and integration of past acquisitions. This mix results in a balanced recommendation profile rather than a clear one-sided view, which is consistent with the relatively moderate implied upside.
Valuation and recent performance
A Zacks commentary on Bristol-Myers Squibb highlights that the stock has gained around 4.3% year to date, while its broader industry benchmark has edged down about 1.3%, underlining a period of relative outperformance. The same piece stresses that the shares still trade at a discount to peers despite this move. The Zacks analysis ties part of the investment case to growth drivers in cardiovascular medicine.
From a pure valuation standpoint, the combination of a single-digit forward earnings multiple and a dividend yield often above the Standard & Poor's 500 index average has kept Bristol-Myers Squibb on the radar of income-oriented and value-focused investors. However, the stock’s trajectory still depends heavily on how convincingly new products fill the revenue gap.
Tuesday lens on analyst expectations
On a Tuesday, the analyst and consensus angle comes into sharper focus for Bristol-Myers Squibb stock. Consensus figures like the $63.08 price target and the fact that the stock trades below that level provide a quantitative snapshot of market expectations at this point in the cycle. Financhill’s summary underpins these numbers.
Beyond the headline target, investors routinely study the spread between the highest and lowest analyst estimates, as well as changes over time. A narrowing range or a cluster of upgraded targets can signal growing conviction, while cuts and wider dispersion usually reflect rising uncertainty around earnings power and pipeline delivery.
The product behind the stock
Bristol-Myers Squibb generates revenue primarily from prescription medicines in oncology, hematology, immunology and cardiovascular disease. Key products include cancer therapies like Opdivo and Eliquis for stroke prevention in patients with atrial fibrillation, alongside a pipeline of new specialty drugs.
Where the stock trades today
The shares of Bristol-Myers Squibb (US1101221083) trade on the New York Stock Exchange at approximately $57.60 as of 06/17/2026, 16:17 CET.
Key facts on Bristol-Myers Squibb stock
- Company: Bristol-Myers Squibb Co.
- ISIN: US1101221083
- WKN: 850501
- Ticker: BMY
- Venue: NYSE
- Price (as of 06/17/2026, 16:17 CET): 57.60 USD
- Market cap: 115,000,000,000 USD (as of 06/17/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: 07/25/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
